N-(3-Aminopropyl)-N-methylcarbamic acid tert-butyl ester is a PROTAC linker that can be used in the synthesis of PROTACs.

Myristoleyl methane sulfonate is a lipid.

Myosin-IN-4 (Compound 3), a pyridine-2,4-dione derivative, is a myocardial myosin inhibitor. Myosin-IN-4 has a strong inhibitory activity against cardiac myosin ATPase with an IC50 value of 0.73 μM. Myosin-IN-4 exert a negative inotropic effect by inhibiting myocardial contraction. Myosin-IN-4 can be used for the research on cardiovascular diseases related to cardiac myosin.

Myosin-IN-3 (Compound 4-1) is a pyrimidine ketone derivative. Myosin-IN-3 exhibits significant anti ferroptotic activity (IC50 = 3.11 μM) while possessing myosin (IC50 = 3.09 μM) inhibitory activity and antioxidant activity (DPPH EC50 = 23.17 μM; MDA EC50 = 55.34 μM). Myosin-IN-3 can be used for research on heart conditions such as hypertrophic cardiomyopathy.

Mutant p53 modulator-2 (Compound 1988) is a mutant p53 modulator. Mutant p53 modulator-2 can be used in the research of cancer.

Multi-target kinase-IN-10 (Compound 6l) is an orally active, blood-brain barrier-permeable, selective, reversible, and competitive MAO-B inhibitor with an IC50 of 0.0053 μM. Multi-target kinase-IN-10 competes with substrates for binding to the active site of MAO-B, chelates Cu2+ ions, inhibits Cu2+-induced ROS production, and reduces the release of NO, TNF-α, and IL-1β. Multi-target kinase-IN-10 ameliorates Parkinson's disease.

Multitarget AD-IN-7 is an orally active multi-target anti-AD compound. Multitarget AD-IN-7 exhibits inhibitory activity against GSK-3β and GSK-3α (IC50 = 0.66, 0.83 nM). Multitarget AD-IN-7 upregulates the expression of p-GSK-3β-Ser9, inhibits the phosphorylation of tau-Ser396, targets Aβ1-42, chelates pathogenic metal ions, scavenges ABTS•+, upregulates the expression of β-catenin and neurogenesis biomarkers, and promotes neurite outgrowth. Multitarget AD-IN-7 improves motor ability in Alzheimer's disease zebrafish. Multitarget AD-IN-7 is applicable to research related to Alzheimer's disease.

Multi-kinase-IN-11 (Compound 1a) is a DFG-out conformation-targeted multi-kinase inhibitor, including SRC, LCK, ABL, PYK2, CSK, HCK, P38 and C-KIT. Multi-kinase-IN-11 serves as a scaffold for the preparation of fluorescently labeled binding probes and affinity matrices.

MU262 is a MUS81 inhibitor with an IC50 value of 0.87 μM. MU262 directly inhibits the catalytic activity of MUS81 without interfering with DNA binding, induces genomic instability in tumor cells, and specifically inhibits the HR/BIR repair pathway. The combination of MU262 with Cisplatin significantly enhances the chemotherapeutic killing effect. MU262 serves as a chemical biology tool for studying MUS81 function, and also acts as a lead compound for the development of anticancer therapies that exploit DNA repair defects in cancer cells.

Mu opioid receptor antagonist 9 is potent, selective and CNS-pentrant mu-opioid receptor (MOR) antagonist with a Ki of 77.3 nM. Mu opioid receptor antagonist 9 exhibits selectivity over kappa-opioid receptor (KOR), and delta-opioid receptor (DOR). Mu opioid receptor antagonist 9 effectively blocks the antinociceptive effects of psychoactive substances. Mu opioid receptor antagonist 9 can reverse psychoactive substances-induced respiratory depression in mice. Mu opioid receptor antagonist 9 can be used for the research of Opioid Use Disorder (OUD).

MT-125 free base is a specific and well-tolerated inhibitor of non-muscle myosin IIA (Ki,NMIIA = 2.7 μM) and IIB (EC50 = 1.7 μM). MT-125 free base can pass through the blood-brain barrier. MT-125 free base induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 free base can enhance the PDGFR signaling pathway. MT-125 free base can be used for research on glioblastoma.

MSU-44147 is an inhibitor and antimicrobial agent targeting MmpL3 in Mycobacterium abscessus, with low eukaryotic cytotoxicity, a narrow antimicrobial spectrum that is specific only to mycobacteria, and low drug resistance frequency. MSU-44147 reduces trehalose dimycolate levels by inhibiting MmpL3 function, disrupts biofilm formation and reduces the viability of related bacteria, while exerting bactericidal effects on intracellular Mycobacterium abscessus. MSU-44147 exhibits additive or synergistic effects with antibiotics and can be used in research on multidrug-resistant isolates and infections of Mycobacterium abscessus.

MS8815N is a negative control of EZH2 PROTAC degrader MS8815. MS8815N is incapable of recruiting the VHL E3 ligase but retains the same EZH2 binding moiety and linker. MS8815N can be used for triple-negative breast cancer (TNBC) research.

MS6178 is a MS5105-based CFTR deubiquitinase-targeted chimera (DUBTAC) that recruits OTUB1 to stabilize ΔF508-CFTR mutant protein in a concentration- and time-dependent manner, with an OTUB1-dependent effect and no impact on CFTR mRNA level. MS6178 can be used for the research of cancer.

MS5105 is a covalent ligand of the deubiquitinating enzyme OTUB1, which can be used to construct DUBTACs, such as MS8588.

MS40 is a WDR5 PROTAC degrader (Kd = 125 nM). MS40 promotes the ubiquitination and degradation of WDR5. MS40-induced WDR5 degradation leads to the dissociation of the MLL/KMT2A complex from chromatin, resulting in decreased H3K4me2 levels. MS40 can be used in the study of primary leukemia.

MS2928 is a selective SETD8 inhibitor with an IC50 of 0.14 μM against SETD8 methyltransferase activity. MS2928 reduces cellular H4K20me1 levels and inhibits proliferation of SETD8-overexpressing multiple myeloma cells. MS2928 inhibits tumor growth in xenograft mouse models of SETD8-overexpressing multiple myeloma. MS2928 can be used for the study of SETD8 biological functions and multiple myeloma.

MS115 TFA is a selective PRMT5/MEP50 PROTAC degrader, with DC50 values of 17.4 nM and 11.3 nM for PRMT5 and MEP50 at 24 h in MDAMB468 cells, respectively. MS115 TFA inhibits the proliferation of breast cancer cells.

MS 857 is an orally active nonglycoside and nonsympathomimetic cardiotonic agent. MS 857 exhibits cardiac and coronary vasodilator effect.

MRS8431 is an ABCG2 inhibitor with a IC50 of 160 nM against human ABCG2. MRS8432 partially inhibits ABCG2-mediated substrate transport. MRS8432 is applicable to research related to cancer multidrug resistance.

MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R in cardiomyocytes. MRS2339 induces ionic currents via cardiomyocyte P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy.

MrgprX2 antagonist-9 (compound 10) is a potent Mas-related G protein-coupled receptor X2 (MrgprX2) antagonist with an IC50 value of 0.1-100 nM. MrgprX2 antagonist-9 has the potential for the research of inflammatory.

MrgprX2 antagonist-10 (Example 218) is a MrgprX2 antagonist with an IC50 of less than 100 nM. MrgprX2 antagonist-10 can be used for the study of various inflammatory diseases.

MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC50 values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection).

MPXV p37 protein-IN-1 is a potent and orally active inhibitor of monkeypox virus (MPXV) p37 protein. MPXV p37 protein-IN-1 exhibits potent antivial activity against MPXV with an EC50 of 12.14 nM, with low cytotoxicity (CC50 = 304.63 μM). MPXV p37 protein-IN-1 demonstrates low toxicity and good tolerability in mice. MPXV p37 protein-IN-1 can be used for the research of anti-MPXV.

MPO-IN-10 is an orally active, selective, and irreversible inhibitor of myeloperoxidase (MPO), with an IC50 of 0.080 μM against human MPO. MPO-IN-10 exhibits higher selectivity for extracellular MPO over intracellular (neutrophil) MPO. MPO-IN-10 can be used in the study of inflammatory diseases such as vascular disorders.

mPEG-DLG (MW 2000) is a PEG-based lipid that can be used to formulate lipid nanoparticles for drug delivery.

MPAM-15 is a blood-brain barrier-penetrant pan-orthosteric allosteric modulator (PAM) of opioid receptors, with ≥16-fold selectivity for μOR over δOR and κOR. MPAM-15 acts as an anti-nociceptive potentiator and analgesic, and its activity is observed in mouse models via both intracerebroventricular and intraperitoneal administration. MPAM-15 is applicable for pain-related research.

MOR antagonist 2 hydrochloride is a blood-brain barrier-permeable μ-opioid receptor (MOR) antagonist, with an IC50 of 28.37 nM, an EC50 of 4.25 nM, and a Ki of 0.18 nM against MOR. MOR antagonist 2 hydrochloride stabilizes the inactive conformation of MOR to reduce receptor activation levels. MOR antagonist 2 hydrochloride antagonizes analgesic effects in the mouse warm-water tail-flick test. MOR antagonist 2 hydrochloride induces fewer opioid withdrawal symptoms (wet dog shakes, paw tremors) in mice with opioid withdrawal symptoms. MOR antagonist 2 hydrochloride can be used for the research of opioid use disorder.

MOR agonist-5 is a selective and potent mu-opioid receptor (MOR) agonist with an EC50 of 0.25 nM. MOR agonist-5 shows an EC50 of 10 nM for DOR and >10000 nM for KOR and NOR. MOR agonist-5 exerts significant antinociceptive activity. MOR agonist-5 can be used for the research of pain.